Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$51.96
Change (%)0.00 (0.00%)
Volume0
Data as of 03/19/19 4:00 p.m. ET
Refresh quote
Featured Events
Corporate Presentation
Download Documentation Corporate Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
03/06/19GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2019, the compensation committee of GBT’s board of directors granted 10 new employees options to purchase an aggregate of 76,100 shares of the company’s common stock with a per share exercise price of $53.48 and restricted stock units for an aggregate of 76,850 shares of the company’s common stock. All of the above-described awards were made under... 
Printer Friendly Version
03/04/19GBT Announces Participation at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March 11, 2019, at 4:50 p.m. Eastern Time. The presentation will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GBT is ... 
Printer Friendly Version
02/27/19GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results
Pre-NDA Meeting Completed and Company Announces FDA Agreed to a Rolling Submission of New Drug Application for Voxelotor for the Potential Treatment of Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the fourth quarter and year ended December 31, 2018. “Last year was successful for GBT as we achieved several important clinical and regulato... 
Printer Friendly Version
02/21/19GBT Announces Participation at the 8th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Thursday, February 28, 2019, at 1 p.m. Eastern Time. The presentation will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GBT i... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.